Semax (ACTH Fragment Peptide)

Semax vs Selank: How They Differ

UKPWritten and published by UK Peptides2 min readUpdated 1 cited source

The short answer

Both were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and both use a Pro-Gly-Pro extension for stability, but their bioactive fragments come from unrelated parent peptides: Semax from ACTH, Selank from tuftsin, an immunomodulatory fragment of immunoglobulin G.

Key facts

Semax parent
ACTH (adrenocorticotropic hormone)
Selank parent
Tuftsin (IgG-derived tetrapeptide)
Shared design feature
Pro-Gly-Pro extension
Common origin
Institute of Molecular Genetics, RAS
Semax PubMed records
~231
Selank PubMed records
~135
Western approval
Neither

The same design philosophy, different starting material

Both peptides follow one strategy: take a short bioactive fragment of a larger endogenous peptide, append Pro-Gly-Pro to make it durable. What differs is the fragment. Semax starts from ACTH, a pituitary hormone. Selank starts from tuftsin, a tetrapeptide derived from the Fc region of immunoglobulin G with described immunomodulatory activity. Those parents have nothing to do with one another.

Why the shared motif does not make them similar

It is easy to read 'both use Pro-Gly-Pro' as implying a family relationship. It does not. The extension is a stabilisation device, not the source of activity; the design assumption in both cases is that the pharmacophore sits in the retained fragment. Two peptides sharing a stabilising tail are no more related than two proteins sharing a purification tag.

Research material referenced

Semax 10mg, third-party HPLC tested

Buy Semax · £24.99

Different research literatures

Semax's literature centres on neurotrophin expression, neuroprotection in ischaemia models and cognition, with roughly 231 indexed records. Selank's centres on anxiolytic and immunomodulatory activity, consistent with its tuftsin origin, with roughly 135. Both share the pattern of internationally published preclinical work alongside clinical literature concentrated in Russian-language journals.

What tuftsin is

Tuftsin is a tetrapeptide, Thr-Lys-Pro-Arg, released from the heavy chain of immunoglobulin G. It was described as stimulating phagocytic activity in macrophages and neutrophils, which is why Selank's reported activity profile leans immunomodulatory in a way Semax's does not.

Shared regulatory position

Neither holds a marketing authorisation from the MHRA, EMA or FDA. Both have Russian registration histories. Both are supplied here for laboratory research only, and the same distinction applies to each: a registration elsewhere is a fact about another regulator's decision, not a therapeutic claim we make.

Quick reference

SemaxSelank
Parent peptideACTHTuftsin (IgG-derived)
Bioactive fragmentACTH(4-7)Tuftsin
Stabilising motifPro-Gly-ProPro-Gly-Pro
Research emphasisNeurotrophins, ischaemiaAnxiolytic, immunomodulatory
PubMed records~231~135
Western approvalNoneNone

Frequently asked questions

Are Semax and Selank the same class of peptide?

They share a design approach and a stabilising motif, but their bioactive fragments come from unrelated parent peptides: ACTH and tuftsin.

Does the Pro-Gly-Pro make them act similarly?

No. It is a stabilisation device rather than the source of activity; the pharmacophore in each sits in the retained fragment.

Is either approved in the West?

Neither. Both hold Russian registration histories and no MHRA, EMA or FDA authorisation.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Semax (ACTH Fragment Peptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.